General information about company

Name of The CompanyTatva Chintan Pharma Chem Limited
BSE Scrip Code543321
NSE SymbolTATVA
MSE SymbolNOTLISTED
Date of Start of Financial Year01-04-2021
Date of End of Financial Year31-03-2022
Reporting PeriodSecond half yearly
Date of Start of Reporting Period01-10-2021
Date of End of Reporting Period31-03-2022
Level of rounding used in financial resultsMillions
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?Yes



Related party transactions

A. Details of related party

Sr1234567891011121314151617181920
Name of the related partyTatva Chintan USA Inc.Tatva Chintan Europe B.VShital Chintan ShahPriti Ajaykumar PatelKajal Shekhar SomaniApurva DubeyAshok BothraIshwar Ramanbhai NayiAjaykumar Mansukhlal PatelChintan Nitinkumar ShahShekhar Rasiklal SomaniAjaykumar Mansukhlal PatelChintan Nitinkumar ShahShekhar Rasiklal SomaniPriti Ajaykumar PatelKajal Shekhar SomaniAjay Mansukhlal Patel HUFDarshana Nitinkumar ShahShitalbhai Rasiklal SomaniSamirkumar Rasiklal Somani
Categories of related partiesSubsidiariesSubsidiariesPromoters GroupPromoters GroupPromoters GroupKey management personnel of entity or parentKey management personnel of entity or parentKey management personnel of entity or parentKey management personnel of entity or parentKey management personnel of entity or parentKey management personnel of entity or parentPromotersPromotersPromotersPromoters GroupPromoters GroupPromoters GroupPromoters GroupPromoters GroupPromoters Group
description of relationshipWholly owned SubsidiaryWholly owned SubsidiaryExecutive MarketingExecutive MarketingExecutive MarketingCompany Secretary & Compliance Officer (Till - 17.01.2022)Chief Financial Officer (with effect from 03.12.2021)Company Secretary & Compliance Officer (with effect from 17.01.2022)Whole-time DirectorManaging DirectorWhole-time DirectorFees & expense related to IPO as per ProspectusFees & expense related to IPO as per ProspectusFees & expense related to IPO as per ProspectusFees & expense related to IPO as per ProspectusFees & expense related to IPO as per ProspectusFees & expense related to IPO as per ProspectusFees & expense related to IPO as per ProspectusFees & expense related to IPO as per ProspectusFees & expense related to IPO as per Prospectus
PAN of related partyZZZZZ9999ZZZZZZ9999ZAFOPS7110QAEDPP1295HAAKPD0835EBNCPD4820RAGFPB9662EAPGPN4130HACSPP6803CAGQPS0271DAKRPS2524AACSPP6803CAGQPS0271DAKRPS2524AAEDPP1295HAAKPD0835EAAGHA5159JANCPS1560JABKPS9106NABKPS9105R
CIN of related party

B. Details of related party transactions

Purchase of goods and services
Sale of goods and services279.3491248.4422
Purchase of fixed assets
Sale of fixed assets
Rendering of services
Receiving of services
Leases
Loans and advances given0.2829
Loans and advances taken
Loans and advances given that are repaid
Loans and advances taken that are repaid
Deposits placed
Deposits taken
Transfer of research & development
Transfers under lease agreement
Equity investment
Impairment in equity investment
Expense for bad or doubtful debts
Guarantees or collateral given
Guarantees or collateral taken
Interest income
Interest paid
Dividend income
Dividend paid
Management contracts including for deputation of employees
Settlement of liabilities by entity on behalf of related party

Remuneration

Short term employee benefits0.150.150.150.13521.56370.16598.25168.25168.2516
Post employment benefits
Other long-term benefits
Termination benefits
Share based payments
Others0.00150.00610.00230.0090.16316.963259.262153.146724.89888.008424.89887.49870.80084.7322

C. Outstanding balances

Receivables

Secured
Un Secured127.6453143.8425

Payables

Secured
Un Secured0.28220.06540.76320.76470.79150.25530.8920.79990.37470.12050.37470.11280.0120.0712

Loans and advances given

Secured
Un Secured

Loans and advances taken

Secured
Un Secured

Deposits placed

Secured
Un Secured

Deposits taken

Secured
Un Secured

Guarantees or collateral given

Secured
Un Secured

Guarantees or collateral taken

Secured
Un Secured

Investment in equity

Secured
Un Secured6.6560.0095

Provision for doubtful debt

Secured
Un Secured

Note

Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders
Reimbursement of issue expenses to Company for the expenses incurred by Company on their behalf for the respective proportion of Equity Shares sold by each Selling Shareholders